Section of Gastroenterology, Department of Surgical, Oncological and Gastroenterological Sciences, Padua University, Italy.
Dig Dis. 2012;30(3):284-8. doi: 10.1159/000336993. Epub 2012 Jun 20.
Therapeutic options in advanced stage hepatocellular carcinoma have been very poor until the discovery of new therapeutic agents that target the molecular pathways involved in hepatocarcinogenesis. In this paper we try to review the most important molecular agents in development, with a specific focus on sorafenib's role and safety profile, especially in the treatment of patients with suboptimal liver function.
在发现针对肝癌发生分子途径的新治疗药物之前，晚期肝癌的治疗选择一直很差。本文我们试图综述最重要的分子药物，特别关注索拉非尼的作用和安全性，特别是在治疗肝功能不佳的患者中的作用。
